Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer

European Surgical Research

Volumn 37, Issue 3, 2005, Pages 166-172

  Terada, H ^a   Urano, T ^a   Konno, H ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Colorectal cancer; Interleukin 8; Liver metastasis; uPA receptor; Urokinase type plasminogen activator; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; UROKINASE RECEPTOR; VASCULOTROPIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; COLORECTAL CANCER; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR GROWTH; TUMOR VOLUME;

COLORECTAL NEOPLASMS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-8; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLASMINOGEN ACTIVATORS; PROBABILITY; PROGNOSIS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23844504745     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085964     Document Type: Article

References (39)

1. Folkman J: Tumor angiogenesis. Adv Cancer Res 1985;43:175-203.
2. Kondo Y, Arii S, Mori A, Furutani M, Chiba T, Imamura M: Enhancement of angiogenesis, tumor growth, and metastasis by transfection of vascular endothelial growth factor into LoVo human colon cancer cell line. Clin Cancer Res 2000;6:622-630.
3. Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE: Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 2000;12:78-85.
4. Matsushima K, Oppenheim JJ: Novel of inflammatory cytokines inducible by IL-1 and TNF. Cytokine 1989;1:2-13.
5. Baggiolini M, Dewaid B, Moser B: Human chemokines: an update. Annu Rev Immunol 1997;15:675-705.
6. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 2000;18:217-242.
7. Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, Yamamoto S, Sumii K, Kajiyama G, Fidler IJ, Tahara E: Regulation of disease progression genes in human gastric carcinoma cells by interleukin-8. Clin Cancer Res 2000;6:2735-2740.
8. Han YP, Hughes MW, Nien YD, Garner WL: IL-8-stimulated expression of urokinase-type plasminogen activator in human skin and human epidermal cells. J Surg Res 2002;106:328-334.
9. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-1039.
10. Pepper MS, Ferrara N, Orci L, Montesano R: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902-906.
11. Unemori EN, Ferrara N, Bauer EA, Amento EP: Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557-562.
12. Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM: Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 1999;59:5412-5416.
13. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-30343.
14. Lissoni P, Malugani F, Bonfanti A, Bucovec R, Secondino S, Brivio F, Ferrari-Bravo A, Ferrante R, Vigore L, Rovelli F, Mandala M, Viviani S, Fumagalli L, Gardani GS: Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 2001;15:140-144.
15. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K: Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998;93:249-252.
16. Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J: Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000;83:1425-1431.
17. Kido S, kitadai Y, Hattori N, Hamura K. Kido T, Ohta M, Tanaka S, Yoshihara M, Sumii K, Ohmoto Y, Chayama K: Interleukin 8 and vascular endothelial growth factor- prognostic factors in human gastric carcinomas? Eur J Cancer 2000;37:1482-1487.
18. Duffy MJ, Reilly D, O'Sullivan C: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990;202:6827-6829.
19. Dano K, Behrendt N, Brunner N, Eliis V, Ploug M, Pyke C: The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8:189-203.
20. Hasui Y, Marutsuka K, Suzumiya J, Kitada S, Osada Y, Sumiyoshi A: The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int J Cancer 1992;50:871-873.
21. Duffy MJ, Reilly D, McDermott E, O'Higgins N, Fennelly JJ, Andreasen PA: Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994;74:2276-2280.
22. Mulcahy HE, Duffy MJ, Gibbons D, McCarthy P, Parfrey NA, O'Donoghue DP: Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994;344:583-584.
23. Sprenger ED, Kluft C: Plasminogen activator inhibitors: Blood 1987;69:381-387.
24. Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR: Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994;54:2900-2907.
25. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994;54:4671-4675.
26. Chambers SK, Ivins CM, Carcagiu HL: Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 1998;79:449-454.
27. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996;134:1563-1571.
28. Stefansson S, Lawrence DA: The serpin PAI-1 inhibits cell migration by blocking integrin Vβ3 binding to vitronectin. Nature 1996;383:441-443.
29. Konno H, Abe J, Kaneko T, Baba M, Shoji A, Sunayama K, Kamiya K, Tanaka T, Suzuki S, Nakamura S, Urano T: Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer. Jpn J Cancer Res 2001;92:516-523.
30. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, Dipietro LA, Elner VM, Einer SG, Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-1801.
31. Li A, Dubey S, Varney ML, Dave BJ, Singh RK: IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-3376.
32. Huang S, Mills L, Mian B, Tellez C, McCarty M Yang XD, Gudas JM, Bar-Eli M: Fully humanized neutralizing antibodies to interleukin 8 (ABX-IL-8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002;161:125-134.
33. Li A, Varney ML, Singh RK: Expression of interleukin 8 and its receptors in human colon carcinoma cells with different metastatic potentials. Clin Cancer Res 2001;7:3298-3304.
34. Marshall LJ, Ramdin L, Brooks TB, Dphil PC, Shute JK: Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/heparan sulfate/syndecan-1 complexes. J Immunol 2003;171:2057-2065.
35. Mandriota SJ, Seghezzi G, Vassalli JD, Ferrera N, Wasi S, Mazzieri R, Mignatti P, Pepper MS: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709-9716.
36. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S: Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-2433.
37. Berny CR, Yang JL, Fisher RJ, Russell PJ: Vascular endothelial growth factor expression is reduced in liver metastasis from colorectal cancer and correlates with urokinase-type plasminogen activator. Anticancer Res 1998;18:973-977.
38. Nakata S, Ito K, Fujimori M, Shingu K, Kajikawa S, Adachi W, Matsuyama I, Tsuchiya S, Kuwano M, Amano J: Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers. Int J Cancer 1998;79:179-186.
39. Masuya D, Huang CL, Liu D, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Haba R, Yokomise H: The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in non-small cell lung carcinoma patients. Cancer 2001;92:2628-2638.